Arvinas shares Phase 1 ARV-102 data for Parkinson's disease

October 7, 2026 7:00 AM

Arvinas, Inc. (Nasdaq: ARVN) presented data from a Phase 1 clinical trial of ARV-102, an investigational oral PROTAC degrader targeting ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found